GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kineta Inc (STU:J75) » Definitions » Additional Paid-In Capital

Kineta (STU:J75) Additional Paid-In Capital : €156.05 Mil(As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Kineta Additional Paid-In Capital?


Kineta's quarterly additional paid-in capital declined from Sep. 2023 (€155.39 Mil) to Dec. 2023 (€154.67 Mil) but then increased from Dec. 2023 (€154.67 Mil) to Mar. 2024 (€156.05 Mil).

Kineta's annual additional paid-in capital increased from Dec. 2021 (€67.38 Mil) to Dec. 2022 (€147.36 Mil) and increased from Dec. 2022 (€147.36 Mil) to Dec. 2023 (€154.67 Mil).


Kineta Additional Paid-In Capital Historical Data

The historical data trend for Kineta's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kineta Additional Paid-In Capital Chart

Kineta Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
44.98 67.38 147.36 154.67

Kineta Quarterly Data
Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 147.53 152.52 155.39 154.67 156.05

Kineta Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Kineta Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Kineta's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Kineta (STU:J75) Business Description

Industry
Traded in Other Exchanges
Address
219 Terry Avenue North, Suite 300, Seattle, WA, USA, 98109
Kineta Inc is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. The company's asset is KVA12.1, a VISTA blocking immunotherapy.

Kineta (STU:J75) Headlines

No Headlines